Joffre J, Yeh C, Wong E, Thete M, Xu F, Zlatanova I
J Immunol. 2020; 204(12):3339-3350.
PMID: 32385136
PMC: 7276941.
DOI: 10.4049/jimmunol.2000213.
Owens R, Mustafa M, Ignatowska-Jankowska B, Damaj M, Beardsley P, Wiley J
Neuropharmacology. 2017; 125:80-86.
PMID: 28673548
PMC: 5771234.
DOI: 10.1016/j.neuropharm.2017.06.032.
Wiley J, Lefever T, Pulley N, Marusich J, Cravatt B, Lichtman A
Behav Pharmacol. 2016; 27(5):479-84.
PMID: 27385208
PMC: 4937884.
DOI: 10.1097/FBP.0000000000000228.
Wiley J, Owens R, Lichtman A
Curr Top Behav Neurosci. 2016; 39:153-173.
PMID: 27278640
DOI: 10.1007/7854_2016_24.
Tanda G
Psychopharmacology (Berl). 2016; 233(10):1845-66.
PMID: 27026633
PMC: 5073892.
DOI: 10.1007/s00213-016-4244-7.
Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.
Ignatowska-Jankowska B, Wilkerson J, Mustafa M, Abdullah R, Niphakis M, Wiley J
J Pharmacol Exp Ther. 2015; 353(2):424-32.
PMID: 25762694
PMC: 4407719.
DOI: 10.1124/jpet.114.222315.
Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.
Panlilio L, Justinova Z, Goldberg S
Pharmacol Ther. 2013; 138(1):84-102.
PMID: 23333350
PMC: 3662489.
DOI: 10.1016/j.pharmthera.2013.01.003.
Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride.
Vann R, Walentiny D, Burston J, Tobey K, Gamage T, Wiley J
Neuropharmacology. 2011; 62(2):1019-27.
PMID: 22051632
PMC: 3262891.
DOI: 10.1016/j.neuropharm.2011.10.011.
Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle.
Wiley J, Walentiny D, Vann R, Baskfield C
Behav Pharmacol. 2011; 22(5-6):480-8.
PMID: 21712709
PMC: 3155614.
DOI: 10.1097/FBP.0b013e328348eced.
The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys.
Stewart J, McMahon L
Br J Pharmacol. 2011; 164(2b):655-66.
PMID: 21449917
PMC: 3188916.
DOI: 10.1111/j.1476-5381.2011.01388.x.
The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice.
Walentiny D, Gamage T, Warner J, Nguyen T, Grainger D, Wiley J
Eur J Pharmacol. 2011; 656(1-3):63-7.
PMID: 21300050
PMC: 3071597.
DOI: 10.1016/j.ejphar.2011.01.056.
Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.
Singh H, Schulze D, McMahon L
Psychopharmacology (Berl). 2011; 215(4):665-75.
PMID: 21246187
PMC: 3140914.
DOI: 10.1007/s00213-010-2162-7.
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.
Giuffrida A, McMahon L
Prostaglandins Other Lipid Mediat. 2009; 91(3-4):90-103.
PMID: 19523530
PMC: 2844932.
DOI: 10.1016/j.prostaglandins.2009.05.004.
Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats.
Murray J, Wells N, Lyford G, Bevins R
Psychopharmacology (Berl). 2009; 205(4):655-65.
PMID: 19495728
DOI: 10.1007/s00213-009-1572-x.
Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon L
Psychopharmacology (Berl). 2008; 203(2):219-28.
PMID: 18592221
PMC: 4879883.
DOI: 10.1007/s00213-008-1230-8.
Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356).
Jarbe T, Lamb R, Liu Q, Makriyannis A
Psychopharmacology (Berl). 2006; 188(3):315-23.
PMID: 16953384
DOI: 10.1007/s00213-006-0517-x.
Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Jarbe T, Liu Q, Makriyannis A
Psychopharmacology (Berl). 2005; 184(1):36-45.
PMID: 16307294
DOI: 10.1007/s00213-005-0225-y.
Self-administration of cannabinoids by experimental animals and human marijuana smokers.
Justinova Z, Goldberg S, Heishman S, Tanda G
Pharmacol Biochem Behav. 2005; 81(2):285-99.
PMID: 15932767
PMC: 2679508.
DOI: 10.1016/j.pbb.2005.01.026.
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data.
Tanda G, Goldberg S
Psychopharmacology (Berl). 2003; 169(2):115-34.
PMID: 12827346
DOI: 10.1007/s00213-003-1485-z.